Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Effectiveness of Nintedanib in Korean Patients

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib

First Posted Date: 2020-08-25

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT04525547

Locations: 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Inje University Ilsan Paik Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 19 locations

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1358894
Drug: Placebo
Drug: Quetiapine

First Posted Date: 2020-08-20

Last Posted Date: 2025-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 389

Registration Number: NCT04521478

Locations: 🇺🇸
CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸
Institute of Living, Hartford, Connecticut, United States
🇺🇸
Gulf Coast Clinical Research Center, Fort Myers, Florida, United States

and more 117 locations

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2020-08-12

Last Posted Date: 2025-01-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6522

Registration Number: NCT04509674

Locations: 🇺🇸
Charlotte Heart Group Research Center, Port Charlotte, Florida, United States
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

and more 429 locations

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Phase 2

Withdrawn

Conditions: Anal Canal Squamous Cell Carcinoma

Interventions: Drug: BI 754091
Drug: BI 836880

First Posted Date: 2020-08-05

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT04499352

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Phase 2

Terminated

Conditions: Palmoplantar Pustulosis

Interventions: Drug: Spesolimab

First Posted Date: 2020-07-30

Last Posted Date: 2024-03-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 108

Registration Number: NCT04493424

Locations: 🇵🇱
Dermoklinika medical center, Lodz, Lodz, Poland
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

and more 63 locations

A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BI 1356225
Drug: Placebo

First Posted Date: 2020-06-25

Last Posted Date: 2021-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 87

Registration Number: NCT04447261

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: Placebo

First Posted Date: 2020-06-24

Last Posted Date: 2021-11-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT04445090

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1595043
Drug: Placebo

First Posted Date: 2020-06-19

Last Posted Date: 2024-02-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT04439838

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1

Recruiting

Conditions: Patients With Small Cell Lung Carcinoma and Other Neoplasms

Interventions: Drug: BI 764532 - parenteral 1
Drug: BI 764532 - parenteral 2

First Posted Date: 2020-06-12

Last Posted Date: 2025-05-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 282

Registration Number: NCT04429087

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 9 locations

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894
Drug: BI 1358894 (C-14) intravenous solution

First Posted Date: 2020-06-11

Last Posted Date: 2025-03-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT04426851

Locations: 🇳🇱
ICON, Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy